Publications by authors named "Rod Junor"

Claim this Profile
A
A Sponsor's Perspective on the Contribution of Regulatory-Required Observational Post-Marketing Studies to Understanding Human Drug Product Benefit/Risk in Japan.
Kevin D Wolter, Asayuki Kamatani, Yumiko Suzuki, Takayuki Imaeda, Ramzi Dagher, Rod Junor

Pharmaceut Med· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multimethod quantitative benefit-risk assessment of treatments for moderate-to-severe osteoarthritis.
Jonathan Mauer, Kristin Bullok, Stephen Watt, Ed Whalen, Leo Russo, Rod Junor

Br J Clin Pharmacol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to: 'Use of tanezumab for patients with hip and knee osteoarthritis with reference to a randomised clinical trial by Berenbaum and colleagues' by Riddle and Perera.
Francis Berenbaum, Francisco J Blanco, Ali Guermazi, Kenji Miki, Takaharu Yamabe, Rod Junor

Ann Rheum Dis· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcutaneous tanezumab for osteoarthritis: Is the early improvement in pain and function meaningful and sustained?
Francis Berenbaum, Richard Langford, Serge Perrot, Kenji Miki, Francisco J Blanco, Rod Junor

Eur J Pain· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period.
Francis Berenbaum, Francisco J Blanco, Ali Guermazi, Kenji Miki, Takaharu Yamabe, Rod Junor

Ann Rheum Dis· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Satisfaction, Adherence and Health-Related Quality of Life with Transdermal Buprenorphine Compared with Oral Opioid Medications in the Usual Care of Osteoarthritis Pain.
Philip G Conaghan, Michael Serpell, Paula McSkimming, Rod Junor, Sara Dickerson

Patient· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of prolonged-release oxycodone/naloxone on outcomes affecting patients' daily functioning in comparison with extended-release tapentadol: a systematic review.
Deepika Thakur, Sara Dickerson, Mohit Kumar Bhutani, Rod Junor

Clin Ther· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis